XTL Biopharmaceuticals Ltd Net Income
| XTLB Stock | USD 0.89 0.02 2.30% |
As of the 14th of February 2026, XTL Biopharmaceutica maintains the Mean Deviation of 5.06, downside deviation of 6.28, and Risk Adjusted Performance of 0.0332. In relation to fundamental indicators, the technical analysis model lets you check available technical drivers of XTL Biopharmaceuticals Ltd, as well as the relationship between them.
XTL Biopharmaceutica Total Revenue |
|
Gross Profit | Quarterly Earnings Growth (0.76) | Market Capitalization | Enterprise Value Revenue 8.7517 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -1.2 M | -1.2 M | |
| Net Loss | -1.6 M | -1.6 M | |
| Net Loss | -1.2 M | -1.2 M | |
| Net Income Per E B T | 1.02 | 0.96 |
XTL | Net Income | Build AI portfolio with XTL Stock |
Analyzing XTL Biopharmaceutica's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing XTL Biopharmaceutica's current valuation and future prospects.
Latest XTL Biopharmaceutica's Net Income Growth Pattern
Below is the plot of the Net Income of XTL Biopharmaceuticals Ltd over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in XTL Biopharmaceuticals financial statement analysis. It represents the amount of money remaining after all of XTL Biopharmaceuticals Ltd operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is XTL Biopharmaceutica's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in XTL Biopharmaceutica's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.03 M) | 10 Years Trend |
|
Net Income |
| Timeline |
XTL Net Income Regression Statistics
| Arithmetic Mean | (1,848,055) | |
| Coefficient Of Variation | (171.90) | |
| Mean Deviation | 1,799,144 | |
| Median | (1,240,102) | |
| Standard Deviation | 3,176,898 | |
| Sample Variance | 10.1T | |
| Range | 15.7M | |
| R-Value | 0.50 | |
| Mean Square Error | 8.1T | |
| R-Squared | 0.25 | |
| Significance | 0.04 | |
| Slope | 314,010 | |
| Total Sum of Squares | 161.5T |
XTL Net Income History
Other Fundumenentals of XTL Biopharmaceuticals
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
XTL Biopharmaceutica Net Income component correlations
XTL Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for XTL Biopharmaceutica is extremely important. It helps to project a fair market value of XTL Stock properly, considering its historical fundamentals such as Net Income. Since XTL Biopharmaceutica's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XTL Biopharmaceutica's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XTL Biopharmaceutica's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. Anticipated expansion of XTL directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive XTL Biopharmaceutica assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.76) | Earnings Share (0.90) | Revenue Per Share | Return On Assets | Return On Equity |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, XTL Biopharmaceutica's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
XTL Biopharmaceutica 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to XTL Biopharmaceutica's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of XTL Biopharmaceutica.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in XTL Biopharmaceutica on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding XTL Biopharmaceuticals Ltd or generate 0.0% return on investment in XTL Biopharmaceutica over 90 days. XTL Biopharmaceutica is related to or competes with Cyclerion Therapeutics, Polyrizon, Vyne Therapeutics, Alaunos Therapeutics, AIM ImmunoTech, Quoin Pharmaceuticals, and Pasithea Therapeutics. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical p... More
XTL Biopharmaceutica Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure XTL Biopharmaceutica's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess XTL Biopharmaceuticals Ltd upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.28 | |||
| Information Ratio | 0.0224 | |||
| Maximum Drawdown | 69.5 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 8.25 |
XTL Biopharmaceutica Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for XTL Biopharmaceutica's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as XTL Biopharmaceutica's standard deviation. In reality, there are many statistical measures that can use XTL Biopharmaceutica historical prices to predict the future XTL Biopharmaceutica's volatility.| Risk Adjusted Performance | 0.0332 | |||
| Jensen Alpha | 0.2294 | |||
| Total Risk Alpha | (0.43) | |||
| Sortino Ratio | 0.0334 | |||
| Treynor Ratio | 0.4004 |
XTL Biopharmaceutica February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0332 | |||
| Market Risk Adjusted Performance | 0.4104 | |||
| Mean Deviation | 5.06 | |||
| Semi Deviation | 5.64 | |||
| Downside Deviation | 6.28 | |||
| Coefficient Of Variation | 3347.49 | |||
| Standard Deviation | 9.37 | |||
| Variance | 87.73 | |||
| Information Ratio | 0.0224 | |||
| Jensen Alpha | 0.2294 | |||
| Total Risk Alpha | (0.43) | |||
| Sortino Ratio | 0.0334 | |||
| Treynor Ratio | 0.4004 | |||
| Maximum Drawdown | 69.5 | |||
| Value At Risk | (10.53) | |||
| Potential Upside | 8.25 | |||
| Downside Variance | 39.4 | |||
| Semi Variance | 31.86 | |||
| Expected Short fall | (6.46) | |||
| Skewness | 3.75 | |||
| Kurtosis | 21.73 |
XTL Biopharmaceuticals Backtested Returns
XTL Biopharmaceutica appears to be out of control, given 3 months investment horizon. XTL Biopharmaceuticals shows Sharpe Ratio of 0.036, which attests that the company had a 0.036 % return per unit of standard deviation over the last 3 months. We have found twenty-nine technical indicators for XTL Biopharmaceuticals, which you can use to evaluate the volatility of the company. Please utilize XTL Biopharmaceutica's Downside Deviation of 6.28, risk adjusted performance of 0.0332, and Mean Deviation of 5.06 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, XTL Biopharmaceutica holds a performance score of 2. The firm maintains a market beta of 0.67, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, XTL Biopharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding XTL Biopharmaceutica is expected to be smaller as well. Please check XTL Biopharmaceutica's maximum drawdown and the relationship between the semi variance and day typical price , to make a quick decision on whether XTL Biopharmaceutica's historical returns will revert.
Auto-correlation | -0.08 |
Very weak reverse predictability
XTL Biopharmaceuticals Ltd has very weak reverse predictability. Overlapping area represents the amount of predictability between XTL Biopharmaceutica time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of XTL Biopharmaceuticals price movement. The serial correlation of -0.08 indicates that barely 8.0% of current XTL Biopharmaceutica price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.08 | |
| Spearman Rank Test | -0.4 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
XTL Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, XTL Biopharmaceuticals Ltd reported net income of (1.03 Million). This is 100.3% lower than that of the Biotechnology sector and 101.47% lower than that of the Health Care industry. The net income for all United States stocks is 100.18% higher than that of the company.
XTL Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XTL Biopharmaceutica's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XTL Biopharmaceutica could also be used in its relative valuation, which is a method of valuing XTL Biopharmaceutica by comparing valuation metrics of similar companies.XTL Biopharmaceutica is currently under evaluation in net income category among its peers.
XTL Biopharmaceutica Current Valuation Drivers
We derive many important indicators used in calculating different scores of XTL Biopharmaceutica from analyzing XTL Biopharmaceutica's financial statements. These drivers represent accounts that assess XTL Biopharmaceutica's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XTL Biopharmaceutica's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 170.4K | 66.6K | 5.1M | 12.0M | 10.8M | 11.3M | |
| Enterprise Value | (2.8M) | (2.0M) | 3.7M | 11.8M | 10.6M | 11.1M |
XTL Biopharmaceutica Institutional Holders
Institutional Holdings refers to the ownership stake in XTL Biopharmaceutica that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of XTL Biopharmaceutica's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing XTL Biopharmaceutica's value.| Shares | Noked Israel Ltd | 2025-06-30 | 198.9 K | Rhumbline Advisers | 2025-06-30 | 17.3 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 11 K | Ubs Group Ag | 2025-06-30 | 1.3 K | Citadel Advisors Llc | 2025-06-30 | 0.0 |
XTL Fundamentals
| Return On Equity | -5.77 | ||||
| Return On Asset | -2.41 | ||||
| Operating Margin | (8.54) % | ||||
| Current Valuation | 8.47 M | ||||
| Shares Outstanding | 9.46 M | ||||
| Shares Owned By Insiders | 38.46 % | ||||
| Shares Owned By Institutions | 2.66 % | ||||
| Number Of Shares Shorted | 212.09 K | ||||
| Price To Earning | 4.50 X | ||||
| Price To Book | 1.90 X | ||||
| Price To Sales | 8.71 X | ||||
| Revenue | 451 K | ||||
| Gross Profit | (2.25 M) | ||||
| EBITDA | (930 K) | ||||
| Net Income | (1.03 M) | ||||
| Cash And Equivalents | 5.16 M | ||||
| Cash Per Share | 0.95 X | ||||
| Total Debt | 138 K | ||||
| Current Ratio | 31.26 X | ||||
| Cash Flow From Operations | (1.62 M) | ||||
| Short Ratio | 0.11 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Target Price | 30.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 0.81 | ||||
| Market Capitalization | 8.43 M | ||||
| Total Asset | 8.55 M | ||||
| Retained Earnings | (159.01 M) | ||||
| Working Capital | (867 K) | ||||
| Current Asset | 3 M | ||||
| Net Asset | 8.55 M |
About XTL Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTL Biopharmaceuticals Ltd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTL Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTL Biopharmaceuticals Ltd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. Anticipated expansion of XTL directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive XTL Biopharmaceutica assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.76) | Earnings Share (0.90) | Revenue Per Share | Return On Assets | Return On Equity |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, XTL Biopharmaceutica's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.